- Title: Subtitle
- Tumor Outcomes of Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer
- Creators
- C.M. Anderson - University of IowaC.M. Lee - Cancer Care NorthwestD. Saunders - Northeast Cancer CentreA.E. Curtis - Spartanburg Regional Medical CenterN.E. Dunlap - University of LouisvilleC. Nangia - University of California, Irvine Medical CenterA. Lee - HOPE Cancer Center of East Texas, Tyler, TXS.M. Gordon - East Carolina UniversityP. Kovoor - Texas OncologyV. Bar-Ad - Thomas Jefferson University HospitalA.V. Peddada - Renown Regional Medical CenterK.T. Colvett - Mountain States Health Alliance, Johnson City, TND.M. Blakaj - James Cancer HospitalM. Bonomi - James Cancer HospitalF. Worden - University of Michigan–Ann ArborJ. Holmlund - Galera Therapeutics, Inc., Malvern, PAJ. Brill - Galera Therapeutics, Inc., Malvern, PAM. Downs - Statistics CollaborativeS.T. Sonis - Primary Endpoint Solutions, Watertown, MAJ. Buatti - University of Iowa
- Resource Type
- Abstract
- Publication Details
- International journal of radiation oncology, biology, physics, Vol.106(5), pp.1221-1222
- Publisher
- Elsevier Inc
- DOI
- 10.1016/j.ijrobp.2020.02.004
- ISSN
- 0360-3016
- eISSN
- 1879-355X
- Language
- English
- Date published
- 04/01/2020
- Academic Unit
- Neurosurgery; Pharmacy Practice and Science; Otolaryngology; Radiation Oncology
- Record Identifier
- 9984305124102771
Abstract
Tumor Outcomes of Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer
International journal of radiation oncology, biology, physics, Vol.106(5), pp.1221-1222
04/01/2020
DOI: 10.1016/j.ijrobp.2020.02.004
Details
Metrics
4 Record Views